Prostate Cancer Chemoprevention

5α-Reductase Inhibitors
  • Jennifer E. Drisko
  • Siu-Long Yao
Part of the Cancer Drug Discovery and Development book series (CDD&D)


5α-reductase is a nuclear membrane-bound NADPH-dependent δ-3-ketosteroid 5α-oxidoreductase. It is found in androgen-sensitive tissues, and catalyzes the conversion of testosterone to dihydrotestosterone (DHT). Two known isoenzymes of 5α-reductase have been identified: Type 1 predominates in peripheral tissues such as the skin and liver, and Type 2 is predominant in the prostate. Finasteride is a specific inhibitor of the Type 2 isoenzyme, and effectively blocks the Type 2-mediated conversion of testosterone to DHT, but does not inhibit the binding of DHT to the androgen receptor (AR) (1).


Prostate Cancer Benign Prostatic Hyperplasia Radical Prostatectomy Prostate Specific Antigen Level Prostate Cancer Prevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    US product circular Medical Economics Company, Inc., for PROSCAR® (finasteride 5 mg tablets), in Physicians’ Desk Reference 53rd ed., Montvale, NJ, 1999, pp.1880–1883.Google Scholar
  2. 2.
    Osterling JE. Prostate-specific antigen: a critical assessment of the most useful marker for adenocarcinoma of the prostate. J Urol 1991;145:907–923.Google Scholar
  3. 3.
    Andriole G, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1998;52:195–201.PubMedCrossRefGoogle Scholar
  4. 4.
    Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17 β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991;16,15–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Carlin JR, Höglund P, Eriksson LO, et al. Disposition and pharmacokinetics of [14C] finasteride after oral administration in humans. Drus Metab Dispos 1992;20,148–155.Google Scholar
  6. 6.
    Huskey SW, Dean DC, Miller RR, et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metal Dispos 1995;23,1126–1135.Google Scholar
  7. 7.
    Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70,1136–1141.PubMedCrossRefGoogle Scholar
  8. 8.
    Stoner E, the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43,284–294.PubMedCrossRefGoogle Scholar
  9. 9.
    Rittmaster RS, Lemay A, Zwicker H, et al. Effects of finasteride, a 5α-reductase inhibitor, on serum gonadotropins in normal men. J Clin Endocrinol Metab 1992;75,484–488.PubMedCrossRefGoogle Scholar
  10. 10.
    Tenover JS, Zeitner ME, Plymate SR. Effects of 24-week administration of a 5α-reductase inhibitor (MK-906) on serum levels of testosterone (T), free T, and gonadotropins in men. Proceedings of 71st Annual Meeting of the Endocrine Society; Program Abstr Endoc Soc Annu Meet 1989;71:abst. S83.Google Scholar
  11. 11.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Gaddipati J, Ahmed T, Friedland M. Prostatic and bladder cancer in the elderly. Clin Geriatr Med 1987;3,649–667.PubMedGoogle Scholar
  13. 13.
    Smith PH, Armitage TG. Immediate vs deferred treatment for early prostatic cancer. Postgrad Med J 1987;63,1055–1060.PubMedCrossRefGoogle Scholar
  14. 14.
    Isaacs JT, Coffey DS. Adaptation vs selection as the mech-anism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981;41,5070–5075.PubMedGoogle Scholar
  15. 15.
    Huggins C, Hodges CV. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1,293–297.Google Scholar
  16. 16.
    Huggins C, Stevens RE, Hodges CV. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1943;43,209–223.CrossRefGoogle Scholar
  17. 17.
    Melamed A. Current concepts in the treatment of prostate cancer. Clin Pharm 1987;21,247–253.Google Scholar
  18. 18.
    Smith J. New methods of endocrine management of prostatic cancer. J Urol 1987;137,1–10.PubMedGoogle Scholar
  19. 19.
    Trump DL, Waldstreicher JA, Kolvenbag G, et al. Androgen antagonists: potential role in prostate cancer prevention. Urology 2001;57 (Suppl 4A):64–67.PubMedCrossRefGoogle Scholar
  20. 20.
    Ross RK, Bernstein L, Judd H, et al. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1976;76:45.Google Scholar
  21. 21.
    Bruun E, Frandsen H, Nielsen K, et al. Dihydrotestosterone measured in core biopsies from prostatic tissues. Am J Clin Oncol 1988 (Suppl 2):S27–S29.Google Scholar
  22. 22.
    Habib FK, Bissas A, Neill WA, et al. Flow cytometric analysis of cellular DNA in human prostate cancer: relationship to 5α-reductase activity of the tissue. Urol Res 1989;17:239–243.PubMedCrossRefGoogle Scholar
  23. 23.
    Muir C, Waterhouse J, Mack T, et al. Cancer Incidence in Five Continents, Vol. V. IARC, Lyon, France, 1987.Google Scholar
  24. 24.
    SEER: Cancer Incidence and Mortality in the United States, 1973–1981. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Bethesda, MD, 1984.Google Scholar
  25. 25.
    Ross RK, Bernstein L, Lobo RA, et al. Evidence for reduced 5α-reductase activity in Japanese compared to US Caucasian and African-American males: implications for prostate cancer risk. Lancet 1992;339:887–889.PubMedCrossRefGoogle Scholar
  26. 26.
    Bologna M, Muzi P, Biordi L et al. Antiandrogens and 5α-reductase inhibition of the proliferation rate in PC3 and DU 145 human prostatic cancer cell lines. Curr Ther Res 1992;51:799–813.Google Scholar
  27. 27.
    Kadoham N, Karr JP, Murphy GP, Sandberg AA. Selective inhibition of prostatic tumor 5α-reductase by a 5-methyl-4-aza-steroid. Cancer Res 1984;44:4947–4954.Google Scholar
  28. 28.
    Petrow V, Padilla GM, Mukherji S, Marts SA. Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone. J Pharm Pharmacol 1984;36:352–353.PubMedCrossRefGoogle Scholar
  29. 29.
    McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. Clin Endocrinol Metab 1992;74,505–508.CrossRefGoogle Scholar
  30. 30.
    Presti JC Jr, Fair WR, Andriole G et al. Multicenter, randomized, double blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148:11,201–11,204.Google Scholar
  31. 31.
    Nacey JN, Meffan PJ, Delahunt B. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia. N Z Med J 1993;106:109–110.Google Scholar
  32. 32.
    Oesterling JE, Roy J, Agha A, et al. Finasteride PSA study group. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Urology 1997;50:13–18.PubMedCrossRefGoogle Scholar
  33. 33.
    Andriole G, Block N, Boake R, et al. Two years of treatment with finasteride after radical prostatectomy. J Urol 1994;151:435A.Google Scholar
  34. 34.
    Andriole G, Lieber M, Smith J, et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45:491–497.PubMedCrossRefGoogle Scholar
  35. 35.
    Jones CD, Audia JE, Lawhorn DE, et al. Nonsteroidal inhibitors of human Type I steroid 5α-reductase. J Med Chem 1993;36:421–423.PubMedCrossRefGoogle Scholar
  36. 36.
    Hirsch KS, Jones CD, Audia JE, et al. LY191704: a selective, nonsteroidal inhibitor of human steriod 5α-reductase Type 1. Proc Natl Acad Sci USA 1993;90:5277–5281.PubMedCrossRefGoogle Scholar
  37. 37.
    Ellsworth K, Azzolina B, Baginsky W, et al. MK386: a potent, selective inhibitor of the human Type 1 5α-reductase. J Steroid Biochem Mol Biol 1996;58:377–384.PubMedCrossRefGoogle Scholar
  38. 38.
    Schwartz JI, Tanaka WK, Wang DZ, et al. MK-386, an inhibitor of 5α-reductase Type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. J Clin Endocrinol Metab 1997;82:1373–1377.PubMedCrossRefGoogle Scholar
  39. 39.
    Harris G, Azzolina B, Baginsky W, et al. Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc Nall Acad Sci USA 1992;89:10,787–10,791.Google Scholar
  40. 40.
    Russell DW, Wilson JD. Steroid 5α-reductase two genes/two enzymes. Annu Rev Biochem 1994;63:25–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Investig 1993;92:903–910.PubMedCrossRefGoogle Scholar
  42. 42.
    Thiboutot D, Harris G, Iles V, et al. Activity of the Type 1 5α-reductase exhibits regional difference in isolated sebaceous glands and whole skin. J Invest Dermatol 1995;105:209–214.PubMedCrossRefGoogle Scholar
  43. 43.
    Pelletier G, Luu-The V, Huang XF, Lapointe H, Labrie F. Localization by the situ hybridization of steroid 5α-reductase isozyme gene expression in the human prostate and preputial skin. J Urol 1998;160:577–582.PubMedCrossRefGoogle Scholar
  44. 44.
    Habib FK, Ross M, Bayne CW, et al. The localization and expression of 5α-reductase Type I and Type II mRNAs in human hyperplastic prostate and in prostate primary cultures. J Endocrinol 1998;156:509–517.PubMedCrossRefGoogle Scholar
  45. 45.
    Iehlé C, Radvanyi F, Diez de Medina, SG, et al. Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999;68:189–195.PubMedCrossRefGoogle Scholar
  46. 46.
    Bruchovsky N, Sadar MD, Akakura K, et al. Characterization of 5α-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem 1996;59:397–404.CrossRefGoogle Scholar
  47. 47.
    Span PN, Benraad TJ, Sweep CGJ, Smals AGH. Kinetic analysis of steroid 5α-reductase activity of neutral pH in benign prostatic hyperplastic tissue: evidence for Type I isozyme activity in the human prostate. J Steroid Biochem Mol Biol 1996;57:103–110.PubMedCrossRefGoogle Scholar
  48. 48.
    Smith CM, Ballard SA, Worman N, et al. 5α-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab 1996;81:1361–1366.PubMedCrossRefGoogle Scholar
  49. 49.
    Negri-Cesi P, Poletti A, Colciago A, et al. Presence of 5α-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 1998;34:283–291.PubMedCrossRefGoogle Scholar
  50. 50.
    Silver RI, Wiley EL, Davis DL, et al. Expression and regulation of steroid 5α-reductase 2 in prostate disease. J Urol 1994;152:433–437.PubMedGoogle Scholar
  51. 51.
    Schwartz JI, Van Hecken A, De Schepper PJ, et al. Effect of MK-386, a novel inhibitor of Type 1 5α-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men. J Clin Endocrinol Metab 1996;81:2942–2947.PubMedCrossRefGoogle Scholar
  52. 52.
    Bakshi RK, Rasmusson GH, Patel GF, et al. 4-Aza-3-oxo5α-androst-1-ene-17 β-N-aryl-carboxamides as dual inhibitors of human Type 1 and Type 2 steroid 5α-reductases. Dramatic effect of N-aryl substituents on Type 1 and Type 2 5α-reductase inhibitory potency. J Med Chem 1995;38:3189–3192.PubMedCrossRefGoogle Scholar
  53. 53.
    Kojo H, Nakayama O, Hirosumi J, et al. Novel steroid 5α-reductase inhibitor FK 143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes. Mol Pharmacol 1995;48:410–406.Google Scholar
  54. 54.
    Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282:1496–1502.PubMedGoogle Scholar
  55. 55.
    Hermann DJ, Davis IM, Wilson TH. Effects of G1198745 (GG745), a novel 5α-reductase (5AR) inhibitor, on dihydrotestosterone (DHT). Am Soc Clin Pharmacol Therapeut 1996;59:162.Google Scholar
  56. 56.
    Hobbs S, Hermann DJ, Gabriel T, et al. Marked suppression of dihydrotestosterone in men by a novel 5α-reductase inhibitor, G1198745. Fertil Steril 1998;70:S455.Google Scholar
  57. 57.
    Dreikorn K, Borkowski A, Braeckman J, et al. Other medical therapies, in 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Denis L, Griffiths, K, Cockett ATK, et al. eds. Plymouth, UK:Plymbridge Distributors Ltd., 1998, pp.635–659.Google Scholar
  58. 58.
    Délos S, Iehlé C, Martin PM. Inhibition of the activity of “basic” 5α-reductase (Type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994;48:347–352.PubMedCrossRefGoogle Scholar
  59. 59.
    Weisser H, Tunn S, Behnke B, Krieg M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia. Prostate 1996;28:300–306.PubMedCrossRefGoogle Scholar
  60. 60.
    Casarosa C, Coscio di Coscio M, Fratta M. Lack of effects of a lyposterolic extract of Seronoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Ther 1988;5:585–588.Google Scholar
  61. 61.
    Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5α-reductase in healthy male volunteers. Eur Urol 1994;26:247–252.PubMedGoogle Scholar
  62. 62.
    Braeckman J. The extract of Serenoa reopens in the treatment of benign prostatic hyperplasia: a multi-center open study. Clin Ther Res 1994;55:776–785.CrossRefGoogle Scholar
  63. 63.
    Champault G, Patel JC, Bonnard A. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984;18:461–462.PubMedCrossRefGoogle Scholar
  64. 64.
    Rhodes L, Primka RL, Berman C, et al. Comparison of Finasteride (Proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition. Prostate 1993;22:43–51.PubMedCrossRefGoogle Scholar
  65. 65.
    Jonas A, Rosenblat G, Krapf D, et al. Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5α-reductase activity, aromatase activity and lipid peroxidation. Urol Res 1998;26:265–270.PubMedCrossRefGoogle Scholar
  66. 66.
    Tunn S, Krieg M. Alterations in the intraprostatic hormonal metabolism by the pollen extract Cernilton®, in Benign Prostatic Disease. Vahlensieck W, Rutishauser G, eds. Thieme Medical Publishers, New York, 1992:109–114.Google Scholar
  67. 67.
    Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Investig 1995;9:291–297.CrossRefGoogle Scholar
  68. 68.
    Reece Smith H, Memon A, Smart CJ, Dewbury K. The value of Permixon in benign prostatic hypertrophy. Br J Urol 1986;58:36–40.PubMedCrossRefGoogle Scholar
  69. 69.
    Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 1996;29:231–224.PubMedCrossRefGoogle Scholar
  70. 70.
    Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451–1456.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Jennifer E. Drisko
  • Siu-Long Yao

There are no affiliations available

Personalised recommendations